Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Hannah Zhang
,
Naranjan S. Dhalla

With cardiovascular disease (CVD) being a primary source of global morbidity and mortality, it is crucial that we understand the molecular pathophysiological mechanisms at play. Recently, numerous pro-inflammatory cytokines have been linked to several different CVDs, which are now often considered an adversely pro-inflammatory state. These cytokines most notably include interleukin-6 (IL-6),tumor necrosis factor (TNF)α, and the interleukin-1 (IL-1) family, amongst others. Not only does inflammation have intricate and complex interactions with pathophysiological processes such as oxidative stress and calcium mishandling, but it also plays a role in the balance between tissue repair and destruction.

  • cardiovascular disease
  • inflammation
  • cytokines
  • cardiomyopathy
  • cardiac remodeling
  • ischemic heart disease
  • heart failure

1. Ischemic Heart Disease

Ischemic heart disease (IHD) comprises a spectrum of diseases that are primarily related to the coronary arteries. It is the most common cause of death globally and is associated with significant morbidity [1]. While traditionally considered synonymous with atherosclerotic disease, we are now beginning to understand the complexities in its pathophysiology beyond just chronic plaque buildup. It is pointed out that inflammation is one branch of the intricate pathway network that has started gathering traction among several investigators.

1.1. Atherosclerosis

Atherosclerosis involves the proliferation of smooth muscle cells, cholesterol deposition in the arterial walls, and infiltration of monocytes. These processes result in lesions that narrow blood vessels and restrict distal flow [2]. Being one of the most common diseases in the world, the link between atherosclerosis and pro-inflammatory cytokines has been quite well-characterized. Vascular smooth muscle cells are known to be a source of IL-6 [3], which has been shown to play an important role in atherosclerosis. In fact, IL-6 injection has been reported to cause significant increases in other pro-inflammatory cytokines, including IL-1β and TNFα, and early development of atherosclerotic lesions [4]. IL-6 mRNA transcripts and proteins were observed to be expressed in the atherosclerotic plaques and arterial walls in humans and rodents at higher rates than non-atherosclerotic artery tissue [2][5][6][7]. Apolipoprotein E (ApoE) and IL-6 double knockout mice were found to have significantly larger and more calcified arterial lesions and no difference in hypercholesterolemia compared to just ApoE knockout animals, and it was suggested that IL-6 expression is important in the formation of fibrous plaque of atheroma [8]. These findings were replicated by Schieffer et al. [9], who showed that IL-6/ApoE double knockout mice have significantly increased atherosclerotic lesions and proposed that IL-6 is important in vascular development, lipid homeostasis, and plaque inflammation.
Another study showed that IL-6 expression in plaques increases with age and lesion intensity in the isolated aortic rings of ApoE knockout mice [6]. While initially seeming contradictory, these studies reinforce the concept that IL-6 plays dual roles, being anti-inflammatory in some circumstances and pro-inflammatory in others. Clinically, higher circulating levels of IL-6 and C-reactive proteins were associated with increased all-cause mortality [10][11], and 6-month mortality was reduced in patients with high IL-6 levels who were given dalteparin therapy [11]. Patients with type 2 diabetes (T2DM) and macrovascular atherosclerosis showed higher levels of circulating IL-6 compared to patients with atherosclerosis and no diabetes, and in combination with levels of TNFα, were better at predicting atherosclerosis development in T2DM patients [12]. Patients with atherosclerosis also had higher levels of IL-6 in the blood than patients without atherosclerosis [12][13], and patients with unstable angina showed higher levels of circulating IL-6 than patients with stable angina [14][15]. IL-6 levels were also higher in patients with ischemic heart failure compared to simple coronary artery disease [16]. Unstable coronary disease patients with complicated hospital courses had higher IL-6 levels than patients with uneventful courses [17]. Coronary artery disease patients who were given an aerobic exercise program in rehabilitation showed reduced circulating levels of pro-inflammatory cytokines, including IL-6 [18]. Overall, it appears that while the complete lifetime absence of IL-6 leads to vascular maladaptation and reduced atherosclerosis in animal models, increased circulating IL-6 levels in patients are associated with the development and severity of atherosclerotic disease.
Both IL-1α and β are secreted by different cell types in the vascular wall, including smooth muscle cells and endothelial cells. When cultured with monocyte-derived IL-1 or human recombinant IL-1, smooth muscle cells produced biologically active IL-1 [19], indicating the presence of this cytokine can stimulate its own expression. Endothelial cells were also shown to produce IL-1 when given inflammatory stimuli such as endotoxin and TNFα [20][21]. IL-1 was observed to be crucial in initiating atherosclerosis in ApoE-deficient mice, as the administration of IL-1Ra significantly reduced fatty streak formation on arterial walls [22][23]. IL-1Ra knockout mice fed an atherogenic diet also had a trend of increased foam cell adhesion area compared to their wildtype littermates, and overexpressing IL-1Ra in LDLR knockout mice was observed to decreased foam cell adhesion area [24]. Aortic sinus atherosclerotic lesions were significantly reduced in ApoE and IL-1β double knockout mice compared to ApoE deficiency alone [25]. IL-1β treatment potentiates vasospasm in pig arteries and caused coronary artery lesions [26]. Clinically, IL-1Ra can be measured as a proxy for IL-1β, and its levels are higher in patients with unstable coronary disease who have a complicated hospital course compared with an uneventful course [17]. Higher IL-1β levels are found in the pericardial fluid of patients with ischemic heart disease compared to valvular and congenital heart disease groups [27]. Clinical trials have been performed to try and target IL-1 to reduce atherosclerotic risk. A randomized control trial called CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) with over 10 thousand patients with previous myocardial infarction received different doses of canakinumab, a monoclonal antibody for IL-1β, or placebo [28]. The highest dose of the drug administered every 3 months resulted in significantly fewer cardiovascular events than placebo, and this result was found to be independent of lipid levels [29]. Canakinumab also reduced the total amount of serious cardiovascular events long-term, with a median follow-up of ~3.7 years [30]. These results suggest the potential of anti-inflammatory therapy targeted at IL-1β for reducing cardiovascular risk.
IL-18 is a pro-inflammatory cytokine that is known to induce IFN-γ activity. Some studies have shown links between this pro-inflammatory cytokine and atherogenesis. When ApoE knockout mice were transfected with IL-18 binding protein (which is the endogenous inhibitor of IL-18), fatty steak development was prevented, and atherosclerotic plaques in the aortic sinus advanced more slowly [31]. In ApoE and IL-18 double knockout mice, the atheromas were significantly smaller and had reduced IFN-γ signaling, although there was increased circulating cholesterol and triglycerides [32]. In humans, carotid intima-media thickness reflected systemic atherosclerosis and was positively correlated with IL-18 concentrations in the blood [33]. Clinically, serum IL-18 levels have been shown to be independent risk predictors for death in patients with coronary atherosclerosis and incidence of coronary events in healthy men [34][35].

1.2. Thrombosis

Thrombosis can occur in the case of atherosclerotic plaque rupture, activating the clotting cascade, and is an important contributor to acute myocardial events. The blood clot can completely obstruct blood flow through the artery, and thus, many pharmacotherapies combating coronary artery disease, such as anticoagulants and anti-platelets, are targeted toward this process. In baboons, TNFα was found to initiate coagulation and fibrinolysis via binding to its p55 receptor (TNFR1) [36]. TNFα and IL-1 were both found to activate endothelial cells, which shifts them to a pro-thrombotic state [37]. In patients with atrial fibrillation, IL-6 levels were higher in patients with increased plasma viscosity, and these patients have an increased risk of stroke [38]. The CANTOS trial also supports the idea that anti-IL-1β therapy could reduce the risk of atherothrombotic disease pathogenesis [29][30].

1.3. Acute Myocardial Infarction

Acute myocardial infarction (AMI) is, as the name suggests, an acute event in which the heart muscle begins to die from severe ischemia. Multiple pro-inflammatory cytokines were secreted from nonmyocytes post-infarction in rats [39]. IL-1β increased bone marrow hematopoietic stem cell proliferation and leukocyte production after AMI in ApoE knockout mice, and anti-IL-1β treatment not only reduced this effect but also diminished post-AMI heart failure [40]. Circulating IL-6 and IL-1β levels were found to be higher in patients with AMI compared to stable angina [41]. Cardiac mast cells were degranulated and released TNFα following myocardial ischemia, which was considered to play a role in upregulating IL-6 levels in leukocytes, leading to a cytokine cascade that caused tissue injury [42]. In one study, circulating levels of IL-6 were elevated at admission and 72-h post-AMI compared to controls, and higher levels of IL-6 expression by peripheral blood mononuclear cells at 72-h post-AMI but not at admission were attributed to the activation by macrophage migration inhibitory factor (MIF) [43]. IL-6 was observed to be a strong predictor of 30-day mortality in patients with AMI complicated by cardiogenic shock [44] and was even a predictor of the risk of future MI in apparently healthy men [45]. IL-1β was associated with myocardial dysfunction and non-infarcted left ventricular mass 1-year after ST-elevation myocardial infarction (STEMI) and served as a potential predictor for maladaptive remodeling of the myocardium following AMI and reperfusion [46].

1.4. Ischemia-Reperfusion Injury

Although reperfusion of ischemic tissue is the gold standard of treatment in clinical practice, ischemia-reperfusion injury (IRI) has been an increasingly apparent unmet need of the healthcare system. IRI is characterized by many complex cellular processes that happen acutely upon reperfusion, including an increased formation of oxygen free radicals, calcium mishandling, and immune activation. These pathways have been observed to result in complications such as myocardial stunning and microvascular dysfunction, often resulting in necrosis [47]. In cultured neonatal rat ventricular myocytes, TNFα was found to increase ROS production and induce mitochondrial DNA damage [48]. This cytokine was released from rat hearts undergoing ischemia-reperfusion (IR) [49][50]. Furthermore, TNFα synthesis was at least partially involved in microvascular transport changes seen in IRI [51]. TNFα knockout mice had reduced infarct sizes following left coronary artery occlusion and improved cardiac function following reperfusion compared to wildtype mice, suggesting that TNFα aggravated IRI via NF-κB activation, which mediates chemokine and adhesion molecule expression and leukocyte infiltration [52]. TNFα also upregulated arginase expression in endothelial cells, which contributes to oxidative stress and endothelial dysfunction in IRI [53]. When given the TNFα inhibitor etanercept before reperfusion, mice had reduced IRI partly via the Notch1 signaling pathway because this agent decreased infarct sizes and improved cardiac function compared to mice with inhibition of the Notch1 pathway [54]. Inhibition of this pathway reduced inducible nitric oxide synthase and enhanced nitric oxide and superoxide production [54]. Anti-TNFα administration at the time of reperfusion reduced superoxide formation and improved coronary dilation in mice, and neutropenic mice had more severe oxidative stress when faced with IRI, indicating TNFα’s deleterious role was neutrophil activation-independent and contributed to oxidative stress and endothelial dysfunction [55].
It may be noted that IL-17A has been shown to induce IRI by activating apoptosis of cardiomyocytes and infiltration of neutrophils. In mice with LAD ligation and reperfusion, IL-17A was elevated, and anti-IL-17A treatment improved infarct size and cardiac function and reduced cardiac troponin-T (cTnT) levels [56]. Necrostatin-1 (Nec-1) decreased cardiomyocyte necrosis and inflammatory cell recruitment by inhibiting the Hmgb1-IL-23/IL-17 pathway and attenuated ROS production in IR [57]. IL-1 receptor type 2, which inhibits 1L-1β signaling, was increased in AMI patients following reperfusion, and its overexpression in cardiomyocytes protected from IL-17A-induced apoptosis [58].

2. Cardiac Remodeling

Most of the prominent cardiac diseases are associated with myocardial remodeling, which is considered to cause heart failure. These changes are generally induced by chronic pressure or volume overload and consist of fibrosis, apoptosis/necrosis, and cardiac hypertrophy. This section is intended to discuss the involvement of pro-inflammatory cytokines in some of the clinical causes and manifestations of the adversely remodeled myocardium, as well as the cellular processes involved in these pathologic transformations. It is also planned to describe the occurrence of adverse remodeling of vascular smooth muscle cells in the pathogenesis of hypertension.

2.1. Hypertension

Chronic hypertension is one of the most common modifiable cardiovascular risk factors in the world, which is known to cause mechanical stress on the myocardium [59]. The activation of the renin-angiotensin system (RAS) and elevated sympathetic nervous system activity are classic characteristics of chronic primary hypertension [60]. Dendritic cells and T-cells are important mediators of hypertension and secrete a multitude of pro-inflammatory cytokines [61]. In conditions of high blood pressure, the endothelium is subjected to increased stretch, which affects monocyte differentiation. When human monocytes were cultured with stretched aortic endothelial cells, mRNA levels for many pro-inflammatory cytokines were upregulated, including IL-6, IL-1β and TNFα [62]. The neutralization of IL-6 and hydrogen peroxide production was shown to inhibit intermediate monocyte differentiation in response to endothelial stretch [62]. Angiotensin II was reported to contribute to the development of hypertension and stimulate IL-6 release from human vascular smooth muscle cells [63][64]. Catecholamines were also found to stimulate IL-6 release from endothelial cells [65]. IL-6 treatment increased the expression of epithelial sodium channels in murine kidney cortical collecting duct cells [66], whereas IL-6 knockout mouse studies have shown that IL-6 is an important mediator of angiotensin II and salt-stimulated hypertension [67][68]. Angiotensin II was observed to stimulate IL-6 release via mineralocorticoid receptor activation in humans [69]. In healthy men, plasma IL-6 levels were reported to exhibit a positive correlation with blood pressure [70], whereas treatment of the blood pressure-lowering drug Irbesartan was observed to lead to decreased systolic and diastolic blood pressures in parallel to decreased IL-6 levels in young hypertensive males [71]. Thus, IL-6 has been shown to contribute to hypertension progression, and its levels are depressed by blood pressure-lowering therapies.
The pleiotropic nature of TNFα was highlighted in hypertension. In vitro and in vivo studies have shown that angiotensin II increases the expression of TNFα in renal tissue [72][73]. TNFα knockout mice did not increase the salt and water intake as well as blood pressure in response to angiotensin II infusion, unlike wildtype mice [74]. Spontaneously hypertensive rats fed high fat and high fructose diets were observed to show increased TNFα concentrations along with overactivity of the RAS [75]. T-cell production of TNFα was also stimulated in hypertensive mice, which was prevented by TNFα inhibitor etanercept [76]. Chronic treatment with etanercept prevented hypertension development in fructose-fed rats [77] and mice with systemic lupus erythematosus [78]. In Sprague-Dawley rats fed a high salt diet and infused with angiotensin II for 2 weeks, etanercept was observed to attenuate blood pressure rise and protect against renal injury [79]; however, studies in spontaneously hypertensive rats with high salt intake did not show any effect of etanercept on blood pressure but instead reduced renal inflammation [80][81]. Mice lacking TNFα, specifically in the renal parenchyma, were protected from angiotensin II-induced hypertension and organ damage but increased endothelial nitric oxide synthase expression in kidneys [82]. In fact, renal expression of TNFα was found to contribute to hypertension in Dahl salt-sensitive rats [83]. Together, these animal studies have suggested that TNFα mediates hypertension through renal physiology and sodium homeostasis, and the effect of its inhibition is dependent upon the type of experimented model. It is also pointed out that neural inhibition of TNFα may also play a role in hypertensive physiology [84][85]. In Japanese women, TNFα levels were associated with increased systolic and diastolic blood pressures [86]. Systolic blood pressure was also correlated with TNFα levels in both Canadian men and women with type 2 diabetes [87]. Hypertensive patients in Mongolia given fish oil supplementation had reductions in TNFα levels compared to control corn oil patients and showed a positive correlation with reduced cardiometabolic risk scores [88]. However, further clinical studies on the effect of TNFα inhibition on hypertension are needed in order to understand its clinical therapeutic potential.

2.2. Cardiac Hypertrophy

Cardiac hypertrophy is the compensatory result of a volume and/or pressure-overloaded heart, often associated with hypertension, and leads to heart failure. There are, however, multiple causes for cardiac hypertrophy, all of which are not pathologic in nature, such as exercise. In vitro studies using cardiomyocytes have shown that IL-6 and IL-6R induce cardiac cell hypertrophy [89][90]. Pressure overload-induced cardiac hypertrophy in mice was found to increase myocardial IL-6 and IL-1β levels, although TNFα levels were not affected [91]. Cardiac fibroblasts induced IL-6 signaling in myocytes to cause cardiac hypertrophy via the p38α pathway [92]. Pathological cardiac hypertrophy was also reported to be a classic feature of sickle cell disease, where hemolysis increased IL-6 expression in mice [93]. Mice undergoing excessive exercise training were observed to show signs of pathologic cardiac hypertrophy and increased expression of pro-inflammatory cytokines, including IL-6 [94]. Inhibition of IL-6 with raloxifene in vitro was shown to reduce the cellular hypertrophy induced by IL-6 treatment [95]. These observations are consistent with the view that IL-6 may play an important role in the development of adverse cardiac remodeling.

2.3. Cardiac Fibrosis

One of the consequences of pro-inflammatory cytokines is tissue repair; however, with limited regenerative capacity, the myocardium has been shown to respond by scar formation [96]. Several immune cells were found to be recruited to the site of injury during this process and contributed to the development of cardiac fibrosis. In the heart, the transition from fibroblast to myofibroblast has been reported to be a key step in this process, as myofibroblasts are known to produce contractile α-smooth muscle actin (α-SMA) and other extracellular matrix (ECM) proteins [97]. It has also been demonstrated that the occurrence of fibrosis is associated with excessive ECM deposition, leading to tissue dysfunction [98]. The expression of multiple pro-inflammatory cytokines post-infarct in cultured rat non-myocyte cardiac cells was also associated with increased collagen production [39]. In vitro, cardiac fibroblast-conditioned media was shown to increase the expression of multiple pro-inflammatory cytokines in cardiomyocytes compared to standard culture conditions [99].
TGF-β is perhaps the most notable cytokine involved in fibrosis. In vascular smooth muscle cells and fibroblasts infected with human TGF-β1 adenovirus, collagen type III gene expression was upregulated [100]. TGF-β stimulated proteoglycan and α-SMA synthesis in cultured myocardial fibroblasts [101][102][103][104]. Mice with TGF-β deleted in the myocardium were found to have decreased cardiac fibrosis and improved survival probability [105]. A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-16 overexpression caused TGF-β activation in cardiac fibroblasts and thus promoted cardiac fibrosis [106]. Wnt/β-catenin pathway signaling increased IL-11 production, which activated TGF-β-mediated fibroblast for transition to myofibroblast [107]. In fact, IL-11 was found to be necessary for the profibrotic action of TGF-β [108]. TGF-β was also demonstrated to play a critical role in the transition between inflammation and fibrosis, as it suppressed inflammation and promoted extracellular matrix deposition [109]. In this context, TGF-β is, therefore, often considered an anti-inflammatory cytokine. Inhibition of TGF-β in mice with aortic constriction was found to result in less fibroblast activation and myocardial fibrosis without any change in cardiac hypertrophy [110]. TGF-β inhibition has been shown to reduce pressure-overload-related cardiac fibrosis in the TAC mouse model of pressure overload [111][112].

2.4. Cardiac Apoptosis and Necrosis

Apoptosis is a deliberate programmed cell death response to physical and chemical stress, thereby acting as a protective mechanism in tissues. Apoptosis has been found to be associated with oxidative stress and calcium overload but usually does not cause notable inflammation [113]. Instead, apoptotic cells express molecules to initiate their phagocytosis, which is a clearance mechanism involving the secretion of anti-inflammatory cytokines such as IL-10 [114]. However, when apoptotic cells are not cleared appropriately, an inflammatory cascade occurs to eliminate a potential threat, starting with the migration of innate immune cells and, later, the accumulation of macrophages [113]. Interestingly, TNFα protected adult murine cardiomyocytes against ischemia-induced apoptosis [115], but mice overexpressing TNFα in cardiac myocytes showed myocardial apoptosis [116]. During the course of human AMI, TNFα was not associated with apoptosis but rather IL-8-induced myocardial apoptosis via the activation and accumulation of neutrophils [117]. On the other hand, necrosis is considered a form of accidental cell death that both causes and is caused by inflammation. In necrosis, cells swell, and the plasma membrane becomes disrupted, thus leaking intracellular contents (DAMPs) as well as triggering an inflammatory response. ROS contributes to necrotic cell death by causing mitochondrial damage, and lipoxygenases can also play a role in cell death. Thus far, TNFα has been the primary inflammatory cytokine that is tied to these cell destruction pathways [113]. These pathways are tightly intertwined with cardiac fibrosis, as they involve the balance between tissue repair and cell death. There are still many unknowns in the relationships between apoptosis, necrosis, and inflammation, as this field is ever-evolving, and more research needs to be carried out to fully understand the mechanisms at play.

2.5. Heart Failure

The result of several diseases and pathogenic mechanisms discussed so far culminate in heart failure, at which point the heart cannot meet the demands of the body. This section will focus on the role of pro-inflammatory cytokines in affecting cardiac contractility and their role in heart failure in a broader sense to better assess the clinical significance. It should be noted that pro-inflammatory cytokines have been shown to alter contractile protein expression in adult rat cardiomyocytes [118]. Infusion of IL-6 induced diastolic dysfunction in rats [119], which is clinically referred to as heart failure with preserved ejection fraction (HFpEF). HFpEF patients were observed to have higher circulating IL-6 and IL-8 levels compared to patients with asymptomatic hypertension [120], and patients with heart failure had higher IL-6 and TNFα levels compared to healthy individuals [121]. Patients with HFpEF who have reduced TNFα levels due to low-level vagus nerve stimulation showed global longitudinal strain improvement and better quality of life [122]. When HFpEF patients were divided into clinical phenogroups, the most functionally impaired group had high levels of TNFα and tissue remodeling and was at the highest risk of cardiovascular death [123].
Higher IL-6 levels were associated with reduced systolic function in apparently healthy individuals, which perhaps served as a predictive marker for heart failure [124]. Circulating IL-6 levels were associated with increased severity of congestive heart failure (CHF) [121][125][126]. Heart explant specimens from patients with advanced heart failure had higher IL-6 and IL-6R transcript levels than controls, and IL-6 levels were inversely correlated with left ventricular ejection fraction [127]. IL-6 was also reported to play a role in post-MI heart failure and affect adverse remodeling [128]. Coronary sinus samples from patients with CHF had high IL-6 and IL-1β levels compared to peripheral venous blood, indicating that these cytokines are secreted into the blood from heart tissue [129]. The signal transducing receptor subunit glycoprotein 130 (gp130) levels for IL-6 were associated with total and cardiovascular mortality and deaths due to HF [130]. Higher IL-6 levels at 48–72 h were associated with all-cause mortality in patients with acute heart failure at 30 days [131]. Physical exercise training in patients with heart failure was reported to reduce IL-6 and TNFα levels and improve functional status [132][133]. It is also noteworthy that in patients with chronic heart failure, there are macrophages that expressed TNFα, which were not present in control patients [134]. Inhibition of TNFα with adenovirus injection in transgenic mice overexpressing TNFα caused a reversal of the dilated cardiomyopathy seen when given no adenovirus [135]. The use of left ventricular assist devices (LVAD) reduced cardiac TNFα levels [136]. Activin A, a member of the TGF-β superfamily, was also implicated in HF [137], although patients with acute CHF showed lower TGF-β1 than patients without CHF [138].

3. Arrhythmias

The electrical activity of the heart is key to coordinating its muscular activity. The cardiac remodeling involving hypertrophy and fibrosis affects the electrical pathways and can be seen to predispose the development of arrhythmias. The following section is focused on discussing the role of pro-inflammatory cytokines in the pathogenesis of some common types of arrhythmias.

3.1. Atrial Fibrillation

Atrial fibrillation (AFIB) is the most common arrhythmia worldwide, with a lifetime risk of 1/3 to 1/5 in people over the age of 40 [139]. The lifestyle risk factors of AFIB, such as hypertension and ischemic heart disease, all involve structural remodeling and chronic inflammation [139]. Several excellent reviews are available in the literature detailing the pathophysiological relationship between inflammation and AFIB [140][141][142]. The role of pro-inflammatory cytokines in AFIB is evident from the observation that calcium mishandling was shown to be mediated by IL-6 for contribution to the development of AFIB in sterile pericarditis rats [143]. The total collagen in left atrial appendage tissue obtained from patients with AFIB was positively correlated with pro-inflammatory cytokines, including IL-6 and TNFα in epicardial adipose tissue [144]. Both IL-6 and TNFα were associated with increased AFIB risk in the general population, and IL-6 was observed during increased risk of postoperative AFIB [145]. Although in patients with coronary artery disease, IL-6 levels were associated with AFIB, but not TNFα [146], IL-6 levels were higher in AFIB patients than non-AFIB controls [147]. A case-control study showed IL-6, IL-8, and TNFα concentrations were independently seen with AFIB patients compared to controls, and graded TNFα levels were associated with paroxysmal, persistent, and permanent AFIB [148]. Patients with AFIB had higher IL-6 levels during AFIB than during sinus rhythm, indicating an acute response during arrhythmia [149].
It has also been reported that cardiac pacing with metoprolol treatment reduced the levels of TNFα and IL-6 in AFIB patients. Furthermore, IL-6 levels were associated with an increased likelihood of AFIB recurrence after ablation [145] and early recurrence after a short-lasting persistent AFIB with rhythm control [150]. Lower levels of TNFα were seen with increases in response to catheter ablation in AFIB patients [151]. In patients with AFIB, baseline IL-6 and TNFα levels were found to be significant predictors for ischemic stroke [152], and IL-6 levels were higher in AFIB patients at high risk of stroke [38]. Elevated IL-6 levels were associated with the prognosis of mortality and adverse cardiovascular events in anti-coagulated patients with AFIB, even when adjusted for the clinical CHADS2 risk stratification score [153]. The pro-fibrotic marker TGF-β was lower in patients with AFIB, declined over increasing AFIB duration, and was negatively correlated with left atrial diameter [138][147]. Together, these data indicate IL-6 may have a role in AFIB by inducing a pro-thrombotic state, whereas both TNFα and IL-6 are involved in the proinflammatory state that potentiates AFIB.

3.2. Other Arrhythmias

There is a lack of studies published about other arrhythmias and pro-inflammatory markers, as they can often be acute events and can result in sudden cardiac death. In atrial flutter patients, the level of IL-6 was higher in peripheral blood than in blood taken from the coronary sinus, indicating a potentially systemic response, with IL-6 level decreasing over time after ablation [154]. Left stellectomy in experimental autoimmune myocarditis rats prevented arrhythmias and reduced IL-6 and TNFα levels [155]. IL-6 has also been shown to be associated with ventricular tachyarrhythmias and an increased risk of sudden cardiac death [156][157][158][159]. IL-18 gene promoter -137 G/C polymorphism was also associated with an increased risk of sudden cardiac death in the context of hypertension [160]. It is noteworthy that connexin-43 (Cx-43), a myocardial gap junction protein, has been implicated in ventricular arrhythmogenesis as it was upregulated by TNFα, thus potentially serving a cardioprotective role in preventing arrhythmias [161]. In young people, TNFα levels were elevated in those with ventricular arrhythmias, and it was suggested that TNFα aggravated arrhythmias [162]. On the other hand, IL-1β caused the loss of Cx-43, reduced the coupling of myocytes and myofibroblasts, and was indicated to be involved in the arrhythmias seen post-MI [163]. It is pointed out that TGF-β1 was released by myofibroblasts to induce changes in sodium and potassium ion channels in rats and was suggested to contribute to the electrical remodeling in myocardial injury [164].

4. Cardiomyopathies

While “cardiomyopathies” is a generic term that refers to a large group of heterogeneous diseases, this section will focus on categories of cardiomyopathies that have not yet been discussed with respect to the role of pro-inflammatory cytokines.

4.1. Autoimmune and Inflammatory Cardiomyopathies

It is not surprising that pro-inflammatory cytokines play a role in cardiomyopathies of infectious or autoimmune origin in rheumatic heart disease (RHD), myocarditis, and pericarditis. It is known that RHD is a major cause of cardiovascular morbidity and mortality in young people, particularly those from developing nations [165]. Group A streptococcal infections can lead to an aberrant immune response, resulting in valvular damage in the heart. One of the hallmarks of RHD lesions is the infiltration of T-lymphocytes. RHD rats were found to show significantly higher serum and mitral valve IL-17 and IL-6 levels, which are Th17-related cytokines, than controls [166]. A similar trend was seen in humans, as patients with RHD had higher circulating IL-6, IL-8, IL-2R, and TNFα levels; IL-6 and TNFα levels correlated with valve calcification and functional class severity [167][168][169][170]. Children with acute rheumatic fever had higher IL-8, IL-2, and IL-1β serum levels compared to those with chronic RHD [171][172]. IL-6 levels were higher, and TNFα levels were lower in patients with acute rheumatic fever [173]. IL-4, IL-8, and IL-1RA were observed to predict clinical RHD vs. latent RHD, along with polymorphisms in the IL-2, IL-4, and IL-6 genes [174]. In heart tissue infiltrates from RHD patients, IFN-γ and TNFα expressing Th1 cells were found to be predominant and were considered to contribute to the valvular damage seen in RHD [175]. In patients with RHD-related mitral stenosis who underwent percutaneous mitral commissurotomy, IL-1β, IL-12, IL-6, and IL-4 were decreased [176]. Overall, the cytokines related to Th1 and Th17 cells appear to be important in the infiltration of valvular tissue in the heart in RHD.
Myocarditis is characterized by inflammation in the myocardium and usually follows a viral infection, but also from bacteria, fungi, and parasites. Myocarditis can also be a drug- or chemical-induced abnormality. Eventually, myocarditis has been shown to result in dilated cardiomyopathy. In acute viral myocarditis, natural killer cells have been observed to enter the heart followed by activated T-cells to induce myocardial damage [177]. Mice hearts infected with Coxsackievirus B3 were found to have a primarily Th1-mediated response, with increases in its related cytokines IL-2, IFN-γ, and TNFβ [177]. In mice infected with encephalomyocarditis-induced dilated cardiomyopathy, IFN-γ, TNFα, and IL1β mRNA levels were increased in the heart tissue 3 days after inoculation, peaked at 7 days post-inoculation, and persisted even 80 days later [178]. On the other hand, IFN-γ-deficient mice developed severe and even fatal autoimmune myocarditis, suggesting a protective role of this cytokine [179][180]. IL-12 induced autoimmune pathways independent of IFN-γ signaling and caused the proliferation of Th1 cells [179]. IL-1 and TNF secreted by inflammatory cells in heart infiltrates contributed to postinfectious autoimmune myocarditis [181]. Non-failing hearts were observed to have IL-1 receptor mRNA expression, while heart tissue from patients with inflammatory myocarditis did not show any IL-1 receptor mRNA expression, suggesting receptor downregulation [182]. IL-1α, TNFα, and M-CSF levels were higher in patients with acute myocarditis [183]. Blockade of IL-1 using anakinra prevented myocardial dysfunction in mice [184]. It should also be mentioned that some studies have examined the role of pro-inflammatory cytokines in pericarditis, which is the inflammation of the pericardium lining the heart. Anakinra, the IL-1 inhibitor, was shown to resolve recurrent pericarditis and its associated symptoms [185][186][187]. IL-1 trap rilonacept also rapidly resolved recurrent pericarditis and prevented subsequent episodes [188]. Although these results suggest a role of IL-1 in the exacerbation of pericarditis episodes, the mechanisms remain unclear.

4.2. Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common inherited genetic heart disease and is the top culprit for sudden death in young people [189]. TGF-β has been implicated in HCM because mutations in sarcomere protein genes and fibrosis are known to contribute to its pathogenesis. In HCM mice, non-myocyte proliferation and fibrosis were observed to be mediated by TGF-β [190]. Mutations in TGF-β inducible early gene-1 (TIEG) were associated with HCM compared to normal hearts [191]. TGF-β gene expression and protein levels were elevated in patients with idiopathic HCM myocardium [192][193][194]. Patients with HCM had higher levels of circulating TGF-β than controls, and TGF-β levels correlated with clinical adverse events and hospitalizations [195]. Additionally, high TNFα and IL-2 levels were detected in patients with HCM [183]. In patients with obstructive HCM undergoing nonsurgical septal reduction, TNFα expression was decreased along with regression of cardiac hypertrophy [196]. IL-6, IL-1β, IL-18, and IL-1Ra levels were elevated in serum and heart tissue in patients with HCM [197][198][199][200][201]. Given the genetic etiology of HCM, however, it is difficult to suggest if targeting pro-inflammatory cytokines is a viable therapeutic option for these patients.

4.3. Diabetic Cardiomyopathy

Diabetic cardiomyopathy is classically considered as a progression to heart failure in diabetic patients in the absence of coronary artery disease, valvular disease, and hypertension, but this definition has not been universally agreed upon by several investigators [202]. It is thought that myocardial fibrosis is an important contributor to the subsequent diastolic heart failure and arrhythmogenesis that develops and, therefore, must be related to glucose homeostasis and sensing. It is noteworthy that fructose has been observed to increase the expression of TGF-β and collagen markers in vitro, and high fructose feeding in mice was found to induce high expression of multiple pro-inflammatory cytokines, including IL-18, IL-6, IL-1β, and TNFα [203]. TGF-β was shown to stimulate NLRP3 in cardiac fibroblasts [204]. In streptozotocin-induced diabetic rats, the NLRP3 inflammasome was activated and resulted in higher circulating IL-1β and IL-18 levels [205]. Mice with diet-induced diabetes had high IL-1β expression in the left ventricle due to NLRP3 inflammasome activation [206]. Diabetic rat hearts also showed higher expression of TNFα compared to control hearts, which was inhibited by consumption of deep-sea mineral extracts [207]. Macrophage migration inhibitory factor (MIF) was also associated with cardiac dysfunction in diabetic patients [208]. In view of these observations, it is suggested that some pro-inflammatory cytokines may play a critical role in the development of diabetic cardiomyopathy.

This entry is adapted from the peer-reviewed paper 10.3390/ijms25021082

References

  1. Severino, P.; D’Amato, A.; Pucci, M.; Infusino, F.; Adamo, F.; Birtolo, L.I.; Netti, L.; Montefusco, G.; Chimenti, C.; Lavalle, C.; et al. Ischemic heart disease pathophysiology paradigms overview: From plaque activation to microvascular dysfunction. Int. J. Mol. Sci. 2020, 21, 8118.
  2. Seino, Y.; Ikeda, U.; Ikeda, M.; Yamamoto, K.; Misawa, Y.; Hasegawa, T.; Kano, S.; Shimada, K. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994, 6, 87–91.
  3. Schrader, J.W.; Moyer, C.; Ziltener, H.J.; Reinisch, C.L. Release of the cytokines colony-stimulating factor-1, granulocyte-macrophage colony-stimulating factor, and IL-6 by cloned murine vascular smooth muscle cells. J. Immunol. 1991, 146, 3799–3808.
  4. Huber, S.A.; Sakkinen, P.; Conze, D.; Hardin, N.; Tracy, R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2364–2367.
  5. Kishikawa, H.; Shimokama, T.; Watanabe, T. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of Cell-Mediated Immunity in Human Atherogenesis. Virchows Arch. A 1993, 423, 433–442.
  6. Sukovich, D.A.; Kauser, K.; Shirley, F.D.; DelVecchio, V.; Halks-Miller, M.; Rubanyi, G.M. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1498–1505.
  7. Rus, H.G.; Vlaicu, R.; Niculescu, F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996, 127, 263–271.
  8. Elhage, R.; Clamens, S.; Besnard, S.; Mallat, Z.; Tedgui, A.; Arnal, J.-F.; Maret, A.; Bayard, F. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17β-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 2001, 156, 315–320.
  9. Schieffer, B.; Selle, T.; Hilfiker, A.; Hilfiker-Kleiner, D.; Grote, K.; Tietge, U.J.F.; Trautwein, C.; Luchtefeld, M.; Schmittkamp, C.; Heeneman, S.; et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 2004, 110, 3493–3500.
  10. Harris, T.B.; Ferrucci, L.; Tracy, R.P.; Corti, M.C.; Wacholder, S.; Ettinger, W.H.; Heimovitz, H.; Cohen, H.J.; Wallace, R. Associations of elevated interleukin-6 and c-reactive protein levels with mortality in the elderly. Am. J. Med. 1999, 106, 506–512.
  11. Lindmark, E.; Diderholm, E.; Wallentin, L.; Siegbahn, A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001, 286, 2107–2113.
  12. Wu, W.; Wang, M.; Sun, Z.; Wang, X.; Miao, J.; Zheng, Z. The predictive value of TNF-α and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol. 2012, 49, 3–7.
  13. Fard, T.K.; Ahmadi, R.; Akbari, T.; Moradi, N.; Fadaei, R.; Fard, M.K.; Fallah, S. Klotho, FOXO1 and cytokines associations in patients with coronary artery disease. Cytokine 2021, 141, 155443.
  14. Biasucci, L.M.; Vitelli, A.; Liuzzo, G.; Altamura, S.; Caligiuri, G.; Monaco, C.; Rebuzzi, A.G.; Ciliberto, G.; Maseri, A. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94, 874–877.
  15. Tashiro, H.; Shimokawa, H.; Yamamoto, K.; Momohara, M.; Tada, H.; Takeshita, A. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron. Artery Dis. 1997, 8, 143–148.
  16. Tentolouris, C.; Tousoulis, D.; Antoniades, C.; Bosinakou, E.; Kotsopoulou, M.; Trikas, A.; Toutouzas, P.; Stefanadis, C. endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int. J. Cardiol. 2004, 94, 301–305.
  17. Biasucci, L.M.; Liuzzo, G.; Fantuzzi, G.; Caligiuri, G.; Rebuzzi, A.G.; Ginnetti, F.; Dinarello, C.A.; Maseri, A. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999, 99, 2079–2084.
  18. Goldhammer, E.; Tanchilevitch, A.; Maor, I.; Beniamini, Y.; Rosenschein, U.; Sagiv, M. Exercise training modulates cytokines activity in coronary heart disease patients. Int. J. Cardiol. 2005, 100, 93–99.
  19. Warner, S.J.; Auger, K.R.; Libby, P. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J. Exp. Med. 1987, 165, 1316–1331.
  20. Libby, P.; Ordovas, J.M.; Birinyi, L.K.; Auger, K.R.; Dinarello, C.A. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J. Clin. Investig. 1986, 78, 1432–1438.
  21. Libby, P.; Ordovas, J.M.; Auger, K.R.; Robbins, A.H.; Birinyi, L.K.; Dinarello, C.A. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am. J. Pathol. 1986, 124, 179–185.
  22. Elhage, R.; Maret, A.; Pieraggi, M.-T.; Thiers, J.C.; Arnal, J.F.; Bayard, F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E–deficient mice. Circulation 1998, 97, 242–244.
  23. Merhi-Soussi, F.; Kwak, B.R.; Magne, D.; Chadjichristos, C.; Berti, M.; Pelli, G.; James, R.W.; Mach, F.; Gabay, C. Interleukin-1 Plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 2005, 66, 583–593.
  24. Devlin, C.M.; Kuriakose, G.; Hirsch, E.; Tabas, I. Genetic Alterations of IL-1 Receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc. Nat. Acad. Sci. USA 2002, 99, 6280–6285.
  25. Kirii, H.; Niwa, T.; Yamada, Y.; Wada, H.; Saito, K.; Iwakura, Y.; Asano, M.; Moriwaki, H.; Seishima, M. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 656–660.
  26. Shimokawa, H.; Ito, A.; Fukumoto, Y.; Kadokami, T.; Nakaike, R.; Sakata, M.; Takayanagi, T.; Egashira, K.; Takeshita, A. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J. Clin. Investig. 1996, 97, 769–776.
  27. Oyama, J.; Shimokawa, H.; Morita, S.; Yasui, H.; Takeshita, A. Elevated interleukin-1β in pericardial fluid of patients with ischemic heart disease. Coron. Artery Dis. 2001, 12, 567–571.
  28. Ridker, P.M.; Thuren, T.; Zalewski, A.; Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am. Heart J. 2011, 162, 597–605.
  29. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017, 377, 1119–1131.
  30. Everett, B.M.; MacFadyen, J.G.; Thuren, T.; Libby, P.; Glynn, R.J.; Ridker, P.M. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J. Am. Coll. Cardiol. 2020, 76, 1660–1670.
  31. Mallat, Z.; Corbaz, A.; Scoazec, A.; Graber, P.; Alouani, S.; Esposito, B.; Humbert, Y.; Chvatchko, Y.; Tedgui, A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 2001, 89, E41–E45.
  32. Elhage, R.; Jawien, J.; Rudling, M.; Ljunggren, H.-G.; Takeda, K.; Akira, S.; Bayard, F.; Hansson, G.K. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 2003, 59, 234–240.
  33. Yamagami, H.; Kitagawa, K.; Hoshi, T.; Furukado, S.; Hougaku, H.; Nagai, Y.; Hori, M. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1458–1462.
  34. Blankenberg, S.; Luc, G.; Ducimetière, P.; Arveiler, D.; Ferrières, J.; Amouyel, P.; Evans, A.; Cambien, F.; Tiret, L.; Group, P.S. Interleukin-18 and the risk of coronary heart disease in European men. Circulation 2003, 108, 2453–2459.
  35. Blankenberg, S.; Tiret, L.; Bickel, C.; Peetz, D.; Cambien, F.; Meyer, J.; Rupprecht, H.J.; Investigators, A. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106, 24–30.
  36. van der Poll, T.; Jansen, P.M.; Zee, K.J.V.; Welborn, M.B.; de Jong, I.; Hack, C.E.; Loetscher, H.; Lesslauer, W.; Lowry, S.F.; Moldawer, L.L. Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 1996, 88, 922–927.
  37. Jurd, K.M.; Stephens, C.J.; Black, M.M.; Hunt, B.J. Endothelial cell activation in cutaneous vasculitis. Clin. Exp. Dermatol. 1996, 21, 28–32.
  38. Conway, D.S.G.; Buggins, P.; Hughes, E.; Lip, G.Y.H. Relationship of interleukin-6 and c-reactive protein to the prothrombotic state in chronic atrial fibrillation. J. Am. Coll. Cardiol. 2004, 43, 2075–2082.
  39. Yue, P.; Massie, B.M.; Simpson, P.C.; Long, C.S. cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am. J. Physiol. Heart Circ. Physiol. 1998, 275, H250–H258.
  40. Sager, H.B.; Heidt, T.; Hulsmans, M.; Dutta, P.; Courties, G.; Sebas, M.; Wojtkiewicz, G.R.; Tricot, B.; Iwamoto, Y.; Sun, Y.; et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 2015, 132, 1880–1890.
  41. Steppich, B.A.; Moog, P.; Matissek, C.; Wisniowski, N.; Kühle, J.; Joghetaei, N.; Neumann, F.-J.; Schomig, A.; Ott, I. Cytokine profiles and t cell function in acute coronary syndromes. Atherosclerosis 2007, 190, 443–451.
  42. Frangogiannis, N.G.; Lindsey, M.L.; Michael, L.H.; Youker, K.A.; Bressler, R.B.; Mendoza, L.H.; Spengler, R.N.; Smith, C.W.; Entman, M.L. Resident cardiac mast cells degranulate and release preformed TNF-α, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 1998, 98, 699–710.
  43. White, D.A.; Fang, L.; Chan, W.; Morand, E.F.; Kiriazis, H.; Duffy, S.J.; Taylor, A.J.; Dart, A.M.; Du, X.-J.; Gao, X.-M. Pro-inflammatory action of MIF in acute myocardial infarction via activation of peripheral blood mononuclear cells. PLoS ONE 2013, 8, e76206.
  44. Andrié, R.P.; Becher, U.M.; Frommold, R.; Tiyerili, V.; Schrickel, J.W.; Nickenig, G.; Schwab, J.O. Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction. Crit. Care 2012, 16, R152.
  45. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101, 1767–1772.
  46. Ørn, S.; Ueland, T.; Manhenke, C.; Sandanger, Ø.; Godang, K.; Yndestad, A.; Mollnes, T.E.; Dickstein, K.; Aukrust, P. Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J. Intern. Med. 2012, 272, 267–276.
  47. Verma, S.; Fedak, P.W.M.; Weisel, R.D.; Butany, J.; Rao, V.; Maitland, A.; Li, R.-K.; Dhillon, B.; Yau, T.M. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002, 105, 2332–2336.
  48. Suematsu, N.; Tsutsui, H.; Wen, J.; Kang, D.; Ikeuchi, M.; Ide, T.; Hayashidani, S.; Shiomi, T.; Kubota, T.; Hamasaki, N.; et al. Oxidative stress mediates tumor necrosis factor-α–induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003, 107, 1418–1423.
  49. Gurevitch, J.; Frolkis, I.; Yuhas, Y.; Paz, Y.; Matsa, M.; Mohr, R.; Yakirevich, V. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J. Am. Coll. Cardiol. 1996, 28, 247–252.
  50. Meldrum, D.R.; Cleveland, J.C.; Cain, B.S.; Meng, X.; Harken, A.H. Increased myocardial tumor necrosis factor-α in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann. Thorac. Surg. 1998, 65, 439–443.
  51. Takenaka, H.; Oshiro, H.; Kim, D.D.; Thompson, P.N.; Seyama, A.; Hobson, R.W.; Durán, W.N. Microvascular transport is associated with tnf plasma levels and protein synthesis in postischemic muscle. Am. J. Physiol. Heart Circ. Physiol. 1998, 274, H1914–H1919.
  52. Maekawa, N.; Wada, H.; Kanda, T.; Niwa, T.; Yamada, Y.; Saito, K.; Fujiwara, H.; Sekikawa, K.; Seishima, M. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-α. J. Am. Coll. Cardiol. 2002, 39, 1229–1235.
  53. Gao, X.; Xu, X.; Belmadani, S.; Park, Y.; Tang, Z.; Feldman, A.M.; Chilian, W.M.; Zhang, C. TNF-α contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1269–1275.
  54. Pei, H.; Song, X.; Peng, C.; Tan, Y.; Li, Y.; Li, X.; Ma, S.; Wang, Q.; Huang, R.; Yang, D.; et al. TNF-α inhibitor protects against myocardial ischemia/reperfusion injury via notch1-mediated suppression of oxidative/nitrative stress. Free Radic. Biol. Med. 2015, 82, 114–121.
  55. Gao, X.; Zhang, H.; Belmadani, S.; Wu, J.; Xu, X.; Elford, H.; Potter, B.J.; Zhang, C. Role of TNF-α-induced reactive oxygen species in endothelial dysfunction during reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H2242–H2249.
  56. Liao, Y.-H.; Xia, N.; Zhou, S.-F.; Tang, T.-T.; Yan, X.-X.; Lv, B.-J.; Nie, S.-F.; Wang, J.; Iwakura, Y.; Xiao, H.; et al. Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J. Am. Coll. Cardiol. 2012, 59, 420–429.
  57. Zhang, A.; Mao, X.; Li, L.; Tong, Y.; Huang, Y.; Lan, Y.; Jiang, H. Necrostatin-1 inhibits Hmgb1-IL-23/IL-17 pathway and attenuates cardiac ischemia reperfusion injury. Transplant. Int. 2014, 27, 1077–1085.
  58. Lin, J.; Li, Q.; Jin, T.; Wang, J.; Gong, Y.; Lv, Q.; Wang, M.; Chen, J.; Shang, M.; Zhao, Y.; et al. Cardiomyocyte IL-1R2 protects heart from ischemia/reperfusion injury by attenuating IL-17RA-mediated cardiomyocyte apoptosis. Cell Death Dis. 2022, 13, 90.
  59. Elliott, W.J. Systemic hypertension. Curr. Probl. Cardiol. 2007, 32, 201–259.
  60. Saxena, T.; Ali, A.O.; Saxena, M. Pathophysiology of essential hypertension: An update. Expert Rev. Cardiovasc. Ther. 2018, 16, 879–887.
  61. Kirabo, A.; Fontana, V.; de Faria, A.P.C.; Loperena, R.; Galindo, C.L.; Wu, J.; Bikineyeva, A.T.; Dikalov, S.; Xiao, L.; Chen, W.; et al. DC Isoketal-modified proteins activate T cells and promote hypertension. J. Clin. Investig. 2014, 124, 4642–4656.
  62. Loperena, R.; Beusecum, J.P.V.; Itani, H.A.; Engel, N.; Laroumanie, F.; Xiao, L.; Elijovich, F.; Laffer, C.L.; Gnecco, J.S.; Noonan, J.; et al. Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: Roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovasc. Res. 2018, 114, 1547–1563.
  63. Kranzhöfer, R.; Schmidt, J.; Pfeiffer, C.A.H.; Hagl, S.; Libby, P.; Kübler, W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 1623–1629.
  64. Han, Y.; Runge, M.S.; Brasier, A.R. Angiotensin II Induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-ΚB transcription factors. Circ. Res. 1999, 84, 695–703.
  65. Gornikiewicz, A.; Sautner, T.; Brostjan, C.; Schmierer, B.; Függer, R.; Roth, E.; Mühlbacher, F.; Bergmann, M. Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells. FASEB J. 2000, 14, 1093–1100.
  66. Li, K.; Guo, D.; Zhu, H.; Hering-Smith, K.S.; Hamm, L.L.; Ouyang, J.; Dong, Y. Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 2010, 299, R590–R595.
  67. Lee, D.L.; Sturgis, L.C.; Labazi, H.; Osborne, J.B.; Fleming, C.; Pollock, J.S.; Manhiani, M.; Imig, J.D.; Brands, M.W. Angiotensin II Hypertension is attenuated in interleukin-6 knockout mice. Am. J. Physiol. Heart Circ. Physiol. 2006, 290, H935–H940.
  68. Coles, B.; Fielding, C.A.; Rose-John, S.; Scheller, J.; Jones, S.A.; O’Donnell, V.B. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 2007, 171, 315–325.
  69. Luther, J.M.; Gainer, J.V.; Murphey, L.J.; Yu, C.; Vaughan, D.E.; Morrow, J.D.; Brown, N.J. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor–dependent mechanism. Hypertension 2006, 48, 1050–1057.
  70. Chae, C.U.; Lee, R.T.; Rifai, N.; Ridker, P.M. Blood pressure and inflammation in apparently healthy men. Hypertension 2001, 38, 399–403.
  71. Vázquez-Oliva, G.; Fernández-Real, J.M.; Zamora, A.; Vilaseca, M.; Badimón, L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J. Hum. Hypertens. 2005, 19, 457–462.
  72. Ferreri, N.R.; Zhao, Y.; Takizawa, H.; McGiff, J.C. Tumor necrosis factor-α-angiotensin interactions and regulation of blood pressure. J. Hypertens. 1997, 15, 1481–1484.
  73. Ferreri, N.R.; Escalante, B.A.; Zhao, Y.; An, S.-J.; McGiff, J.C. Angiotensin II induces TNF production by the thick ascending limb: Functional implications. Am. J. Physiol. Ren. Physiol. 1998, 274, F148–F155.
  74. Sriramula, S.; Haque, M.; Majid, D.S.A.; Francis, J. Involvement of tumor necrosis factor-α in angiotensin II–mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008, 51, 1345–1351.
  75. Szabó, R.; Börzsei, D.; Hoffmann, A.; Lesi, Z.N.; Gesztelyi, R.; Juhász, B.; Szebeni, G.J.; Osman, J.; Sebestyén, J.; Nagy, A.; et al. Lifestyle-Induced redox-sensitive alterations: Cross-talk among the RAAS, antioxidant/inflammatory status, and hypertension. Oxidative Med. Cell. Longev. 2021, 2021, 3080863.
  76. Guzik, T.J.; Hoch, N.E.; Brown, K.A.; McCann, L.A.; Rahman, A.; Dikalov, S.; Goronzy, J.; Weyand, C.; Harrison, D.G. Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction. J. Exp. Med. 2007, 204, 2449–2460.
  77. Tran, L.T.; MacLeod, K.M.; McNeill, J.H. Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol. Cell. Biochem. 2009, 330, 219–228.
  78. Venegas-Pont, M.; Manigrasso, M.B.; Grifoni, S.C.; LaMarca, B.B.; Maric, C.; Racusen, L.C.; Glover, P.H.; Jones, A.V.; Drummond, H.A.; Ryan, M.J. Tumor necrosis factor-α antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 2010, 56, 643–649.
  79. Elmarakby, A.A.; Quigley, J.E.; Pollock, D.M.; Imig, J.D. Tumor necrosis factor α blockade increases renal cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 2006, 47, 557–562.
  80. Elmarakby, A.A.; Quigley, J.E.; Imig, J.D.; Pollock, J.S.; Pollock, D.M. TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 2008, 294, R76–R83.
  81. Snyder, E.C.; Abdelbary, M.; El-Marakby, A.; Sullivan, J.C. Treatment of male and female spontaneously hypertensive rats with TNF-α inhibitor etanercept increases markers of renal injury independent of an effect on blood pressure. Biol. Sex. Differ. 2022, 13, 17.
  82. Zhang, J.; Patel, M.B.; Griffiths, R.; Mao, A.; Song, Y.; Karlovich, N.S.; Sparks, M.A.; Jin, H.; Wu, M.; Lin, E.E.; et al. Tumor necrosis factor-α produced in the kidney contributes to angiotensin II–dependent hypertension. Hypertension 2018, 64, 1275–1281.
  83. Huang, B.; Cheng, Y.; Usa, K.; Liu, Y.; Baker, M.A.; Mattson, D.L.; He, Y.; Wang, N.; Liang, M. Renal tumor necrosis factor α contributes to hypertension in Dahl salt-sensitive rats. Sci. Rep. 2016, 6, 21960.
  84. Sriramula, S.; Cardinale, J.P.; Francis, J. Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension. PLoS ONE 2013, 8, e63847.
  85. Song, X.-A.; Jia, L.-L.; Cui, W.; Zhang, M.; Chen, W.; Yuan, Z.-Y.; Guo, J.; Li, H.-H.; Zhu, G.-Q.; Liu, H.; et al. Inhibition of TNF-α in hypothalamic paraventricular nucleus attenuates hypertension and cardiac hypertrophy by inhibiting neurohormonal excitation in spontaneously hypertensive rats. Toxicol. Appl. Pharm. 2014, 281, 101–108.
  86. Ito, H.; Ohshima, A.; Tsuzuki, M.; Ohto, N.; Takao, K.; Hijii, C.; Yanagawa, M.; Ogasawara, M.; Nishioka, K. Association of serum tumour necrosis factor-α with serum low-density lipoprotein–cholesterol and blood pressure in apparently healthy Japanese women. Clin. Exp. Pharmacol. Physiol. 2001, 28, 188–192.
  87. Zinman, B.; Hanley, A.J.G.; Harris, S.B.; Kwan, J.; Fantus, I.G. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J. Clin. Endocrinol. Metabol. 1999, 84, 272–278.
  88. Yang, B.; Ren, X.; Li, Z.; Shi, M.; Ding, F.; Su, K.-P.; Guo, X.; Li, D. Lowering effects of fish oil supplementation on proinflammatory markers in hypertension: Results from a randomized controlled trial. Food Funct. 2020, 11, 1779–1789.
  89. Kumar, S.; Wang, G.; Zheng, N.; Cheng, W.; Ouyang, K.; Lin, H.; Liao, Y.; Liu, J. HIMF (hypoxia-induced mitogenic factor)-IL (interleukin)-6 signaling mediates cardiomyocyte-fibroblast crosstalk to promote cardiac hypertrophy and fibrosis. Hypertension 2019, 73, 1058–1070.
  90. Hirota, H.; Yoshida, K.; Kishimoto, T.; Taga, T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Nat. Acad. Sci. USA 1995, 92, 4862–4866.
  91. Zhang, M.L.; Li, Z.P.; Xiao, H. Different expressions of inflammatory cytokines in two types of cardiac hypertrophy in rats. J. Peking Univ. Health Sci. 2007, 39, 570–575.
  92. Bageghni, S.A.; Hemmings, K.E.; Zava, N.; Denton, C.P.; Porter, K.E.; Ainscough, J.F.X.; Drinkhill, M.J.; Turner, N.A. Cardiac fibroblast-specific p38α map kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism. FASEB J. 2018, 32, 4941–4954.
  93. Gbotosho, O.T.; Kapetanaki, M.G.; Ghosh, S.; Villanueva, F.S.; Ofori-Acquah, S.F.; Kato, G.J. Heme induces IL-6 and cardiac hypertrophy genes transcripts in sickle cell mice. Front. Immunol. 2020, 11, 1910.
  94. da Rocha, A.L.; Teixeira, G.R.; Pinto, A.P.; Morais, G.P.; Oliveira, L.d.C.; de Vicente, L.G.; da Silva, L.E.C.M.; Pauli, J.R.; Cintra, D.E.; Ropelle, E.R.; et al. Excessive training induces molecular signs of pathologic cardiac hypertrophy. J. Cell. Physiol. 2018, 233, 8850–8861.
  95. Huo, S.; Shi, W.; Ma, H.; Yan, D.; Luo, P.; Guo, J.; Li, C.; Lin, J.; Zhang, C.; Li, S.; et al. Alleviation of inflammation and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via IL-6/STAT3 inhibition by raloxifene. Oxidative Med. Cell. Longev. 2021, 2021, 6699054.
  96. Prabhu, S.D.; Frangogiannis, N.G. The biological basis for cardiac repair after myocardial infarction. Circ. Res. 2016, 119, 91–112.
  97. Saadat, S.; Noureddini, M.; Mahjoubin-Tehran, M.; Nazemi, S.; Shojaie, L.; Aschner, M.; Maleki, B.; Abbasi-kolli, M.; Moghadam, H.R.; Alani, B.; et al. Pivotal role of TGF-β/Smad signaling in cardiac fibrosis: Non-coding RNAs as effectual players. Front. Cardiovasc. Med. 2021, 7, 588347.
  98. Hinderer, S.; Schenke-Layland, K. Cardiac Fibrosis—A short review of causes and therapeutic strategies. Adv. Drug Deliv. Rev. 2019, 146, 77–82.
  99. LaFramboise, W.A.; Scalise, D.; Stoodley, P.; Graner, S.R.; Guthrie, R.D.; Magovern, J.A.; Becich, M.J. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am. J. Physiol. Cell Physiol. 2007, 292, C1799–C1808.
  100. Villarreal, F.J.; Lee, A.A.; Dillmann, W.H.; Giordano, F.J. Adenovirus-mediated overexpression of human transforming growth factor-β1 in rat cardiac fibroblasts, myocytes and smooth muscle cells. J. Mol. Cell. Cardiol. 1996, 28, 735–742.
  101. Heimer, R.; Bashey, R.I.; Kyle, J.; Jimenez, S.A. TGF-β Modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. J. Mol. Cell. Cardiol. 1995, 27, 2191–2198.
  102. Shephard, P.; Martin, G.; Smola-Hess, S.; Brunner, G.; Krieg, T.; Smola, H. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-β and interleukin-1. Am. J. Pathol. 2004, 164, 2055–2066.
  103. Desmoulière, A.; Geinoz, A.; Gabbiani, F.; Gabbiani, G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993, 122, 103–111.
  104. Eghbali, M.; Tomek, R.; Woods, C.; Bhambi, B. Cardiac fibroblasts are predisposed to convert into myocyte phenotype: Specific effect of transforming growth factor beta. Proc. Nat. Acad. Sci. USA 1991, 88, 795–799.
  105. Bhandary, B.; Meng, Q.; James, J.; Osinska, H.; Gulick, J.; Valiente-Alandi, I.; Sargent, M.A.; Bhuiyan, S.; Blaxall, B.C.; Molkentin, J.D.; et al. Cardiac fibrosis in proteotoxic cardiac disease is dependent upon myofibroblast TGF-β signaling. J. Am. Heart Assoc. 2018, 7, e010013.
  106. Yao, Y.; Hu, C.; Song, Q.; Li, Y.; Da, X.; Yu, Y.; Li, H.; Clark, I.M.; Chen, Q.; Wang, Q.K. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Cardiovasc. Res. 2019, 116, 956–969.
  107. Działo, E.; Czepiel, M.; Tkacz, K.; Siedlar, M.; Kania, G.; Błyszczuk, P. WNT/β-catenin signaling promotes TGF-β-mediated activation of human cardiac fibroblasts by enhancing IL-11 production. Int. J. Mol. Sci. 2021, 22, 10072.
  108. Schafer, S.; Viswanathan, S.; Widjaja, A.A.; Lim, W.-W.; Moreno-Moral, A.; DeLaughter, D.M.; Ng, B.; Patone, G.; Chow, K.; Khin, E.; et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 2017, 552, 110–115.
  109. Xia, Y.; Lee, K.; Li, N.; Corbett, D.; Mendoza, L.; Frangogiannis, N.G. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem. Cell Biol. 2009, 131, 471–481.
  110. Kuwahara, F.; Kai, H.; Tokuda, K.; Kai, M.; Takeshita, A.; Egashira, K.; Imaizumi, T. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106, 130–135.
  111. Li, N.; Hang, W.; Shu, H.; Zhou, N. Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF-β1/Smad3 signalling pathway. J. Cell. Mol. Med. 2022, 26, 4548–4555.
  112. Wei, H.; Bedja, D.; Koitabashi, N.; Xing, D.; Chen, J.; Fox-Talbot, K.; Rouf, R.; Chen, S.; Steenbergen, C.; Harmon, J.W.; et al. Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling. Proc. Nat. Acad. Sci. USA 2012, 109, E841–E850.
  113. Yang, Y.; Jiang, G.; Zhang, P.; Fan, J. Programmed cell death and its role in inflammation. Mil. Med. Res. 2015, 2, 12.
  114. Rock, K.L.; Kono, H. The inflammatory response to cell death. Annu. Rev. Pathol. Mech. Dis. 2008, 3, 99–126.
  115. Kurrelmeyer, K.M.; Michael, L.H.; Baumgarten, G.; Taffet, G.E.; Peschon, J.J.; Sivasubramanian, N.; Entman, M.L.; Mann, D.L. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc. Nat. Acad. Sci. USA 2000, 97, 5456–5461.
  116. Bryant, D.; Becker, L.; Richardson, J.; Shelton, J.; Franco, F.; Peshock, R.; Thompson, M.; Giroir, B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation 1998, 97, 1375–1381.
  117. Akasaka, Y.; Morimoto, N.; Ishikawa, Y.; Fujita, K.; Ito, K.; Kimura-Matsumoto, M.; Ishiguro, S.; Morita, H.; Kobayashi, Y.; Ishii, T. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod. Pathol. 2006, 19, 588–598.
  118. Patten, M.; Krämer, E.; Bünemann, J.; Wenck, C.; Thoenes, M.; Wieland, T.; Long, C. Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo. Pflügers Arch. 2001, 442, 920–927.
  119. Meléndez, G.C.; McLarty, J.L.; Levick, S.P.; Du, Y.; Janicki, J.S.; Brower, G.L. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010, 56, 225–231.
  120. Collier, P.; Watson, C.J.; Voon, V.; Phelan, D.; Jan, A.; Mak, G.; Martos, R.; Baugh, J.A.; Ledwidge, M.T.; McDonald, K.M. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur. J. Heart Fail. 2011, 13, 1087–1095.
  121. Fedacko, J.; Singh, R.B.; Gupta, A.; Hristova, K.; Toda, E.; Kumar, A.; Saxena, M.; Baby, A.; Singh, R.; Toru, T.; et al. Inflammatory mediators in chronic heart failure in north india. Acta Cardiol. 2014, 69, 391–398.
  122. Stavrakis, S.; Elkholey, K.; Morris, L.; Niewiadomska, M.; Asad, Z.U.A.; Humphrey, M.B. Neuromodulation of inflammation to treat heart failure with preserved ejection fraction: A pilot randomized clinical trial. J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis. 2021, 11, e023582.
  123. Cohen, J.B.; Schrauben, S.J.; Zhao, L.; Basso, M.D.; Cvijic, M.E.; Li, Z.; Yarde, M.; Wang, Z.; Bhattacharya, P.T.; Chirinos, D.A.; et al. Clinical phenogroups in heart failure with preserved ejection fraction detailed phenotypes, prognosis, and response to spironolactone. J. Am. Coll. Cardiol. Heart Fail. 2020, 8, 172–184.
  124. Yan, A.T.; Yan, R.T.; Cushman, M.; Redheuil, A.; Tracy, R.P.; Arnett, D.K.; Rosen, B.D.; McClelland, R.L.; Bluemke, D.A.; Lima, J.A.C. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: Insights from the multi-ethnic study of atherosclerosis. Eur. Heart J. 2010, 31, 875–882.
  125. Hirota, H.; Izumi, M.; Hamaguchi, T.; Sugiyama, S.; Murakami, E.; Kunisada, K.; Fujio, Y.; Oshima, Y.; Nakaoka, Y.; Yamauchi-Takihara, K. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessel. 2004, 19, 237–241.
  126. Torre-Amione, G.; Kapadia, S.; Benedict, C.; Oral, H.; Young, J.B.; Mann, D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol. 1996, 27, 1201–1206.
  127. Gabriele, P.; Zhi Fang, S.; Tonny, D.T.T.; Carsten, K.; Hideo, A.B.; Michael, E.; Markus, F.; Thomas, W.; Hans, H.S.; Mario, C.D. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur. J. Heart Fail. 2001, 3, 415–421.
  128. Hilfiker-Kleiner, D.; Shukla, P.; Klein, G.; Schaefer, A.; Stapel, B.; Hoch, M.; Müller, W.; Scherr, M.; Theilmeier, G.; Ernst, M.; et al. Continuous glycoprotein-130–mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 2010, 122, 145–155.
  129. Stanciu, A.E.; Stanciu, M.M.; Vatasescu, R.G. NT-ProBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. Cytokine 2018, 111, 13–19.
  130. Askevold, E.T.; Nymo, S.; Ueland, T.; Gravning, J.; Wergeland, R.; Kjekshus, J.; Yndestad, A.; Cleland, J.G.F.; McMurray, J.J.V.; Aukrust, P.; et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure. Circ. Heart Fail. 2018, 6, 91–98.
  131. Perez, A.L.; Grodin, J.L.; Chaikijurajai, T.; Wu, Y.; Hernandez, A.F.; Butler, J.; Metra, M.; Felker, G.M.; Voors, A.A.; McMurray, J.J.; et al. Interleukin-6 and outcomes in acute heart failure: An ASCEND-HF substudy. J. Card. Fail. 2021, 27, 670–676.
  132. Adamopoulos, S.; Parissis, J.; Karatzas, D.; Kroupis, C.; Georgiadis, M.; Karavolias, G.; Paraskevaidis, J.; Koniavitou, K.; Coats, A.J.S.; Kremastinos, D.T. Physical training modulates proinflammatory cytokines and the soluble fas/soluble fasligand system in patients with chronic heart failure. J. Am. Coll. Cardiol. 2002, 39, 653–663.
  133. Fernandes-Silva, M.M.; Guimarães, G.V.; Rigaud, V.O.; Lofrano-Alves, M.S.; Castro, R.E.; Cruz, L.G.d.B.; Bocchi, E.A.; Bacal, F. Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: Insights from a randomized clinical trial. Eur. J. Prev. Cardiol. 2017, 24, 808–817.
  134. Devaux, B.; Scholz, D.; Hirche, A.; Klövekorn, W.P.; Schaper, J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur. Heart J. 1997, 18, 470–479.
  135. Kubota, T.; Bounoutas, G.S.; Miyagishima, M.; Kadokami, T.; Sanders, V.J.; Bruton, C.; Robbins, P.D.; McTiernan, C.F.; Feldman, A.M. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000, 101, 2518–2525.
  136. Maybaum, S.; Mancini, D.; Xydas, S.; Starling, R.C.; Aaronson, K.; Pagani, F.D.; Miller, L.W.; Margulies, K.; McRee, S.; Frazier, O.H.; et al. Cardiac improvement during mechanical circulatory support. Circulation 2007, 115, 2497–2505.
  137. Yndestad, A.; Ueland, T.; Øie, E.; Florholmen, G.; Halvorsen, B.; Attramadal, H.; Simonsen, S.; Frøland, S.S.; Gullestad, L.; Christensen, G.; et al. Elevated levels of activin a in heart failure. Circulation 2004, 109, 1379–1385.
  138. Behnes, M.; Hoffmann, U.; Lang, S.; Weiss, C.; Ahmad-Nejad, P.; Neumaier, M.; Borggrefe, M.; Brueckmann, M. Transforming growth factor beta 1 (TGF-Beta 1) in atrial fibrillation and acute congestive heart failure. Clin. Res. Cardiol. 2011, 100, 335–342.
  139. Kornej, J.; Börschel, C.S.; Benjamin, E.J.; Schnabel, R.B. epidemiology of atrial fibrillation in the 21st century. Circ. Res. 2020, 127, 4–20.
  140. Hu, Y.-F.; Chen, Y.-J.; Lin, Y.-J.; Chen, S.-A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 2015, 12, 230–243.
  141. Scott, L.; Li, N.; Dobrev, D. Role of inflammatory signaling in atrial fibrillation. Int. J. Cardiol. 2019, 287, 195–200.
  142. Harada, M.; Wagoner, D.R.V.; Nattel, S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ. J. 2015, 79, 495–502.
  143. Liao, J.; Zhang, S.; Yang, S.; Lu, Y.; Lu, K.; Wu, Y.; Wu, Q.; Zhao, N.; Dong, Q.; Chen, L.; et al. Interleukin-6-mediated-Ca2+ handling abnormalities contributes to atrial fibrillation in sterile pericarditis rats. Front. Immunol. 2021, 12, 758157.
  144. Abe, I.; Teshima, Y.; Kondo, H.; Kaku, H.; Kira, S.; Ikebe, Y.; Saito, S.; Fukui, A.; Shinohara, T.; Yufu, K.; et al. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm. 2018, 15, 1717–1727.
  145. Wu, N.; Xu, B.; Xiang, Y.; Wu, L.; Zhang, Y.; Ma, X.; Tong, S.; Shu, M.; Song, Z.; Li, Y.; et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int. J. Cardiol. 2013, 169, 62–72.
  146. Marcus, G.M.; Whooley, M.A.; Glidden, D.V.; Pawlikowska, L.; Zaroff, J.G.; Olgin, J.E. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the heart and soul study. Am. Heart J. 2008, 155, 303–309.
  147. Stanciu, A.E.; Vatasescu, R.G.; Stanciu, M.M.; Serdarevic, N.; Dorobantu, M. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine 2018, 103, 63–68.
  148. Li, J.; Solus, J.; Chen, Q.; Rho, Y.H.; Milne, G.; Stein, C.M.; Darbar, D. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010, 7, 438–444.
  149. Marcus, G.M.; Smith, L.M.; Ordovas, K.; Scheinman, M.M.; Kim, A.M.; Badhwar, N.; Lee, R.J.; Tseng, Z.H.; Lee, B.K.; Olgin, J.E. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010, 7, 149–154.
  150. Smit, M.D.; Maass, A.H.; Jong, A.M.D.; Kobold, A.C.M.; Veldhuisen, D.J.V.; Gelder, I.C.V. Role of inflammation in early atrial fibrillation recurrence. Europace 2012, 14, 810–817.
  151. Kimura, T.; Takatsuki, S.; Inagawa, K.; Katsumata, Y.; Nishiyama, T.; Nishiyama, N.; Fukumoto, K.; Aizawa, Y.; Tanimoto, Y.; Tanimoto, K.; et al. Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation. Heart Lung Circ. 2014, 23, 636–643.
  152. Pinto, A.; Tuttolomondo, A.; Casuccio, A.; Di Raimondo, D.; Di Sciacca, R.; Arnao, V.; Licata, G. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin. Sci. 2009, 116, 781–789.
  153. Roldán, V.; Marín, F.; Díaz, J.; Gallego, P.; Jover, E.; Romera, M.; Manzano-Fernández, S.; Casas, T.; Valdés, M.; Vicente, V.; et al. High sensitivity cardiac troponin t and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J. Thromb. Haemost. 2012, 10, 1500–1507.
  154. Marcus, G.M.; Smith, L.M.; Glidden, D.V.; Wilson, E.; McCabe, J.M.; Whiteman, D.; Tseng, Z.H.; Badhwar, N.; Lee, B.K.; Lee, R.J.; et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm. 2008, 5, 215–221.
  155. Park, H.; Park, H.; Mun, D.; Kim, M.; Pak, H.-N.; Lee, M.-H.; Joung, B. Sympathetic nerve blocks promote anti-inflammatory response by activating the JAK2-STAT3–mediated signaling cascade in rat myocarditis models: A novel mechanism with clinical implications. Heart Rhythm. 2018, 15, 770–779.
  156. Parekh, R.S.; Plantinga, L.C.; Kao, W.H.L.; Meoni, L.A.; Jaar, B.G.; Fink, N.E.; Powe, N.R.; Coresh, J.; Klag, M.J. The Association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int. 2008, 74, 1335–1342.
  157. Empana, J.-P.; Jouven, X.; Canouï-Poitrine, F.; Luc, G.; Tafflet, M.; Haas, B.; Arveiler, D.; Ferrieres, J.; Ruidavets, J.-B.; Montaye, M.; et al. C-Reactive protein, interleukin 6, fibrinogen and risk of sudden death in european middle-aged men: The PRIME study. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2047–2052.
  158. Safranow, K.; Dziedziejko, V.; Rzeuski, R.; Czyżycka, E.; Bukowska, H.; Wojtarowicz, A.; Bińczak-Kuleta, A.; Jakubowska, K.; Olszewska, M.; Ciechanowicz, A.; et al. Inflammation markers are associated with metabolic syndrome and ventricular arrhythmia in patients with coronary artery disease. Postępy Hig. Med. Doświadczalnej 2016, 70, 56–66.
  159. Streitner, F.; Kuschyk, J.; Veltmann, C.; Brueckmann, M.; Streitner, I.; Brade, J.; Neumaier, M.; Bertsch, T.; Schumacher, B.; Borggrefe, M.; et al. Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipients—A pilot study. Cytokine 2007, 40, 30–34.
  160. Hernesniemi, J.A.; Karhunen, P.J.; Oksala, N.; Kähönen, M.; Levula, M.; Rontu, R.; Ilveskoski, E.; Kajander, O.; Goebeler, S.; Viiri, L.E.; et al. Interleukin 18 gene promoter polymorphism: A link between hypertension and pre-hospital sudden cardiac death: The helsinki sudden death study. Eur. Heart J. 2009, 30, 2939–2946.
  161. Salameh, A.; Schneider, P.; Mühlberg, K.; Hagendorff, A.; Dhein, S.; Pfeiffer, D. Chronic regulation of the expression of gap junction proteins connexin40, connexin43, and connexin45 in neonatal rat cardiomyocytes. Eur. J. Pharmacol. 2004, 503, 9–16.
  162. Kowalewski, M.; Urban, M.; Mroczko, B.; Szmitkowski, M. Proinflammatory cytokines (IL-6, TNF-Alpha) and cardiac troponin I (CTnI) in serum of young people with ventricular arrhythmias. Pol. Arch. Med. Wewn. 2002, 108, 647–651.
  163. Baum, J.R.; Long, B.; Cabo, C.; Duffy, H.S. Myofibroblasts cause heterogeneous cx43 reduction and are unlikely to be coupled to myocytes in the healing canine infarct. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H790–H800.
  164. Kaur, K.; Zarzoso, M.; Ponce-Balbuena, D.; Guerrero-Serna, G.; Hou, L.; Musa, H.; Jalife, J. TGF-Β1, Released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. PLoS ONE 2013, 8, e55391.
  165. Marijon, E.; Mirabel, M.; Celermajer, D.S.; Jouven, X. Rheumatic heart disease. Lancet 2012, 379, 953–964.
  166. Wen, Y.; Zeng, Z.; Gui, C.; Li, L.; Li, W. Changes in the expression of Th17 cell-associated cytokines in the development of rheumatic heart disease. Cardiovasc. Pathol. 2015, 24, 382–387.
  167. Davutoglu, V.; Celik, A.; Aksoy, M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J. Heart Valve Dis. 2005, 14, 251–256.
  168. Chen, M.-C.; Chang, H.-W.; Wu, C.-J.; Yang, C.-H.; Yu, T.-H.; Chen, C.-J.; Hung, W.-C. Balance between plasma levels of tumor necrosis factor-α and interleukin-10 in rheumatic mitral stenosis. Cardiology 2005, 104, 171–175.
  169. Yeğin, O.; Coşkun, M.; Ertuğ, H. Cytokines in acute rheumatic fever. Eur. J. Pediatr. 1996, 156, 25–29.
  170. Soares, A.C.D.; Passos, L.S.A.; Sable, C.; Beaton, A.; Ribeiro, V.T.; Gollob, K.J.; Dutra, W.O.; Nunes, M.C.P. Circulating cytokines predict severity of rheumatic heart disease. Int. J. Cardiol. 2019, 289, 107–109.
  171. Kütükçüler, N.; Narin, N. Plasma Interleukin-7 (IL-7) and IL-8 Concentrations in acute rheumatic fever and chronic rheumatic heart disease. Scand. J. Rheumatol. 1995, 24, 383–385.
  172. Narin, N.; Kütükçüler, N.; özyürek, R.; Bakiler, A.R.; Parlar, A.; Arcasoy, M. Lymphocyte subsets and plasma IL-1 α, IL-2, and TNF-α concentrations in acute rheumatic fever and chronic rheumatic heart disease. Clin. Immunol. Immunopathol. 1995, 77, 172–176.
  173. Ozgen, H.; Ucar, B.; Yildirim, A.; Colak, O.; Bal, C.; Kilic, Z. Plasma adiponectin levels and relations with cytokines in children with acute rheumatic fever. Cardiol. Young 2015, 25, 879–892.
  174. Tormin, J.P.A.S.; Nascimento, B.R.; Sable, C.A.; da Silva, J.L.P.; Brandao-de-Resende, C.; Rocha, L.P.C.; Pinto, C.H.R.; Neves, E.G.A.; Macedo, F.V.B.; Fraga, C.L.; et al. Cytokine gene functional polymorphisms and phenotypic expression as predictors of evolution from latent to clinical rheumatic heart disease. Cytokine 2021, 138, 155370.
  175. Guilherme, L.; Cury, P.; Demarchi, L.M.F.; Coelho, V.; Abel, L.; Lopez, A.P.; Oshiro, S.E.; Aliotti, S.; Cunha-Neto, E.; Pomerantzeff, P.M.A.; et al. Rheumatic heart disease proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am. J. Pathol. 2004, 165, 1583–1591.
  176. Silva, V.R.; Neves, E.G.A.; Passos, L.S.A.; deMelo, F.C.; Teixeira-Carvalho, A.; Nassif, M.C.L.; Junqueira, L.L.; Aikawa, E.; Dutra, W.O.; Nunes, M.C.P. Decreased cytokine plasma levels and changes in t-cell activation are associated with hemodynamic improvement and clinical outcomes after percutaneous mitral commissurotomy in patients with rheumatic mitral stenosis. Front. Cardiovasc. Med. 2021, 7, 604826.
  177. Seko, Y.; Takahashi, N.; Yagita, H.; Okumura, K.; Yazaki, Y. Expression of cytokine mrnas in murine hearts with acute myocarditis caused by coxsackievirus B3. J. Pathol. 1997, 183, 105–108.
  178. Shioi, T.; Matsumori, A.; Sasayama, S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 1996, 94, 2930–2937.
  179. Eriksson, U.; Kurrer, M.O.; Sebald, W.; Brombacher, F.; Kopf, M. Dual role of the IL-12/IFN-γ axis in the development of autoimmune myocarditis: Induction by IL-12 and protection by IFN-γ. J. Immunol. 2001, 167, 5464–5469.
  180. Eriksson, U.; Kurrer, M.O.; Bingisser, R.; Eugster, H.P.; Saremaslani, P.; Follath, F.; Marsch, S.; Widmer, U. Lethal Autoimmune myocarditis in interferon-γ receptor–deficient mice. Circulation 2001, 103, 18–21.
  181. Lane, J.R.; Neumann, D.A.; Lafond-Walker, A.; Herskowitz, A.; Rose, N.R. Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J. Immunol. 1993, 151, 1682–1690.
  182. Han, R.O.; Ray, P.E.; Baughman, K.L.; Feldman, A.M. Detection of Interleukin and interleukin-receptor mRNA in human heart by polymerase chain reaction. Biochem. Biophys. Res. Commun. 1991, 181, 520–523.
  183. Matsumori, A.; Yamada, T.; Suzuki, H.; Matoba, Y.; Sasayama, S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 1994, 72, 561–566.
  184. Gorelik, M.; Lee, Y.; Abe, M.; Andrews, T.; Davis, L.; Patterson, J.; Chen, S.; Crother, T.R.; Aune, G.J.; Rivas, M.N.; et al. IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of kawasaki disease vasculitis and myocarditis. Clin. Exp. Immunol. 2019, 198, 101–110.
  185. Camprubí, D.; Mitjavila, F.; Arostegui, J.I.; Corbella, X. Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant. Int. J. Rheum. Dis. 2017, 20, 510–514.
  186. Brucato, A.; Imazio, M.; Gattorno, M.; Lazaros, G.; Maestroni, S.; Carraro, M.; Finetti, M.; Cumetti, D.; Carobbio, A.; Ruperto, N.; et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: The AIRTRIP Randomized clinical trial. JAMA 2016, 316, 1906–1912.
  187. Buckley, L.F.; Viscusi, M.M.; Tassell, B.W.V.; Abbate, A. Interleukin-1 blockade for the treatment of pericarditis. Eur. Heart J. Cardiovasc. Pharmacother. 2017, 4, 46–53.
  188. Klein, A.L.; Imazio, M.; Cremer, P.; Brucato, A.; Abbate, A.; Fang, F.; Insalaco, A.; LeWinter, M.; Lewis, B.S.; Lin, D.; et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N. Engl. J. Med. 2020, 384, 31–41.
  189. Maron, B.J.; Maron, M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381, 242–255.
  190. Teekakirikul, P.; Eminaga, S.; Toka, O.; Alcalai, R.; Wang, L.; Wakimoto, H.; Nayor, M.; Konno, T.; Gorham, J.M.; Wolf, C.M.; et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-β. J. Clin. Investig. 2010, 120, 3520–3529.
  191. Bos, J.M.; Subramaniam, M.; Hawse, J.R.; Christiaans, I.; Rajamannan, N.M.; Maleszewski, J.J.; Edwards, W.D.; Wilde, A.A.M.; Spelsberg, T.C.; Ackerman, M.J. TGFβ-inducible early gene-1 (TIEG1) mutations in hypertrophic cardiomyopathy. J. Cell. Biochem. 2012, 113, 1896–1903.
  192. Li, R.-K.; Li, G.; Mickle, D.A.G.; Weisel, R.D.; Merante, F.; Luss, H.; Rao, V.; Christakis, G.T.; Williams, W.G. Overexpression of transforming growth factor-β1 and insulin-like growth factor-i in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997, 96, 874–881.
  193. Li, G.; Borger, M.A.; Williams, W.G.; Weisel, R.D.; Mickle, D.A.G.; Wigle, E.D.; Li, R.-K. Regional overexpression of insulin-like growth factor-i and transforming growth factor-β1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2002, 123, 89–95.
  194. Li, G.; Li, R.K.; Mickle, D.A.; Weisel, R.D.; Merante, F.; Ball, W.T.; Christakis, G.T.; Cusimano, R.J.; Williams, W.G. Elevated insulin-like growth factor-i and transforming growth factor-beta 1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy. a possible mechanism. Circulation 1998, 98, II144–II149, discussion II149–II150.
  195. Ayça, B.; Sahin, I.; Kucuk, S.H.; Akin, F.; Kafadar, D.; Avşar, M.; Avci, I.I.; Gungor, B.; Okuyan, E.; Dinckal, M.H. Increased transforming growth factor-β levels associated with cardiac adverse events in hypertrophic cardiomyopathy. Clin. Cardiol. 2015, 38, 371–377.
  196. Nagueh, S.F.; Stetson, S.J.; Lakkis, N.M.; Killip, D.; Perez-Verdia, A.; Entman, M.L.; III, W.H.S.; Torre-Amione, G. Decreased expression of tumor necrosis factor-α and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001, 103, 1844–1850.
  197. Mándi, Y.; Hőgye, M.; Talha, E.M.; Skolák, E.; Csanády, M. cytokine production and antibodies against heat shock protein 60 in cardiomyopathies of different origins. Pathobiology 2001, 68, 150–158.
  198. Kuusisto, J.; Kärjä, V.; Sipola, P.; Kholová, I.; Peuhkurinen, K.; Jääskeläinen, P.; Naukkarinen, A.; Ylä-Herttuala, S.; Punnonen, K.; Laakso, M. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart 2012, 98, 1007–1013.
  199. Buzás, K.; Megyeri, K.; Hõgye, M.; Csanády, M.; Bogáts, G.; Mándi, Y. Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies. Eur. Cytokine Netw. 2004, 15, 53–59.
  200. Zen, K.; Irie, H.; Doue, T.; Takamiya, M.; Yamano, T.; Sawada, T.; Azuma, A.; Matsubara, H. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy. Int. Heart J. 2005, 46, 231–244.
  201. Hassoun, R.; Budde, H.; Zhazykbayeva, S.; Herwig, M.; Sieme, M.; Delalat, S.; Mostafi, N.; Gömöri, K.; Tangos, M.; Jarkas, M.; et al. Stress activated signalling impaired protein quality control pathways in human hypertrophic cardiomyopathy. Int. J. Cardiol. 2021, 344, 160–169.
  202. Lorenzo-Almorós, A.; Cepeda-Rodrigo, J.M.; Lorenzo, Ó. Diabetic cardiomyopathy. Rev. Clínica Española Engl. Ed. 2022, 222, 100–111.
  203. Zhang, Y.; Zhang, Y. Toll-like receptor-6 (TLR6) deficient mice are protected from myocardial fibrosis induced by high fructose feeding through anti-oxidant and inflammatory signaling pathway. Biochem. Bioph Res. Commun. 2016, 473, 388–395.
  204. Bracey, N.A.; Gershkovich, B.; Chun, J.; Vilaysane, A.; Meijndert, H.C.; Wright, J.R.; Fedak, P.W.; Beck, P.L.; Muruve, D.A.; Duff, H.J. Mitochondrial NLRP3 protein induces reactive oxygen species to promote smad protein signaling and fibrosis independent from the inflammasome*. J. Biol. Chem. 2014, 289, 19571–19584.
  205. Zhang, X.; Pan, L.; Yang, K.; Fu, Y.; Liu, Y.; Chi, J.; Zhang, X.; Hong, S.; Ma, X.; Yin, X. H3 relaxin protects against myocardial injury in experimental diabetic cardiomyopathy by inhibiting myocardial apoptosis, fibrosis and Inflammation. Cell. Physiol. Biochem. 2017, 43, 1311–1324.
  206. Fender, A.C.; Kleeschulte, S.; Stolte, S.; Leineweber, K.; Kamler, M.; Bode, J.; Li, N.; Dobrev, D. Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart. Basic. Res. Cardiol. 2020, 115, 10.
  207. Lu, C.; Ou, H.; Day, C.; Chen, H.; Pai, P.; Lee, C.; Chen, R.; Chang, R.; PadmaViswanadha, V.; Hsieh, D.J.; et al. Deep sea minerals ameliorate diabetic-induced inflammation via inhibition of TNFα signaling pathways. Environ. Toxicol. 2020, 35, 468–477.
  208. Yu, X.-Y.; Chen, H.-M.; Liang, J.-L.; Lin, Q.-X.; Tan, H.-H.; Fu, Y.-H.; Liu, X.-Y.; Shan, Z.-X.; Li, X.-H.; Yang, H.-Z.; et al. Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: Macrophage migration inhibitory factor. PLoS ONE 2011, 6, e16239.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback